Researchers report possibility of using unused human pancreata to build new organs

December 10, 2015

WINSTON-SALEM, N.C. - December 10, 2015 - Researchers have been working for years to develop an artificial pancreas in the lab to help the millions of people with type 1 diabetes. But what if the answer is to "recycle" the more than 300 human pancreata from organ donors that aren't currently being used?

Online ahead of print in the Annals of Surgery, regenerative medicine researchers at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine and colleagues report on the potential to use human pancreata as the "hardware" of a new-generation, bio-artificial pancreas. The pancreas is a large gland near the stomach that secretes insulin to regulate the metabolism of glucose and other nutrients.

Currently, about 25 percent of the approximately 1,300 pancreata recovered for transplant cannot be used due to defects and other reasons.

"We see these unused organs as potential 'hardware." The 'software' would be the patient's own cells, so that there would be no issues with rejection," said lead author Giuseppe Orlando, M.D., Ph.D., a transplant surgeon and regenerative medicine researcher. "We believe this research represents the first critical step toward a fully human-derived artificial pancreas."

Currently, most patients who have type 1 diabetes must take injections of insulin because their bodies do not produce insulin to regulate blood sugar levels. Other options, such as a pancreas transplant or transplant of insulin-producing islet cells are rarely offered due to the lack of suitable pancreas donors and the toxic effects of anti-rejection drugs. In the U.S., for every 10,000 patients with type 1 diabetes, only three will receive a pancreas transplant or islet transplant in their lifetime, according to the authors.

The goal of the research was to test the suitability of pancreata from organ donors as a platform for building a new bio-artificial pancreas. First, the discarded organs were washed in a mild detergent to remove all cells, a process that is known as decellularization. A similar procedure is being used by Wake Forest Baptist regenerative medicine researchers in efforts to engineer human kidneys, livers and intestine.

The goal of both projects is to develop a new, potentially inexhaustible source of organs that would not require patients to take powerful anti-rejection drugs. The idea is based on evidence that the decellularized organs contain proteins and other substances that play a vital role in the survival, welfare and function of the organ's cells.

For the study, 25 human pancreata were processed to remove cells. The researchers found that the framework of blood vessels remained intact after the washing process. In addition, the researchers are the first to report that numerous growth factors were retained in the structures. Some of these proteins are essential in blood vessel formation, cell proliferation and glucose metabolism.

In theory, these organ structures could be re-populated with a patient's own cells. Insulin-producing cells could be generated from the patient's skin cells or could come from the patient's pancreas. Cells to line the organ's blood vessels (endothelial cells) could also come from the patient's pancreas. To test the compatibility of the decellularized structures and new cells, the researchers placed both insulin-producing and endothelial cells on the decellularized structures. In both cases, the organs structures were cell-friendly and allowed the cells to attach, function and maintain their original cell type.

Next, to test the ability of the structures to grow new blood vessels, small samples of the cell-coated pancreata structures were implanted in chicken eggs. The structures integrated well with the developing environment of the chicken egg and generated capillaries. For the first time, the authors also conducted immunological tests to understand whether the structures would be rejected by the immune system. Surprisingly, they found that the structures actually regulated the immune response, suggesting that the engineered pancreata could be used as adjuvant immunosuppressants.

"The early results are encouraging and pave the way for further investigations to understand the interactions between the organ structures and cells and to identify the optimal cell type to achieve complete regeneration of the endothelium and islets," said Orlando.

In addition to the current research, Orlando represents Wake Forest Baptist as the only U.S.-based researcher on a $9 million project to develop a cell-therapy product to treat diabetes. The four-year effort, BIOCAPAN, is funded by the European Commission. Orlando's role is to use regenerative medicine technologies to distill non-cellular materials from discarded pancreata. The research team hypothesizes that the material may support the function of insulin-producing cells and can form the basis of a new insulin-free treatment for diabetes. (This project has received funding from the European Union's Horizon2020 research and innovation programme under grant agreement No 646272).
The research reported in the Annals of Surgery is supported by unrestricted funds from Liberitutti Foundation.

Co-authors of the study were: Andrea Peloso, M.D., Ph.D., Ravi Katari, B.S., Guoguang Niu, PhD, John P. McQuilling, Ph.D., Sivanandane Sittadjody, Ph.D., Alan C. Farney, M.D., Ph.D., Samy S. Iskandar, MBBCh. Ph.D., Jeffrey Rogers, M.D., Robert J. Stratta, M.D., Emmanuel C. Opara, Ph.D., Cristina M Furdui, Ph.D., and Shay Soker, Ph.D., Wake Forest Baptist; Luca Urbani, Ph.D., Panagiotis Maghsoudlou, B.S., Mario Enrique Alvarez Fallas, B.S., and Paolo De Coppi, M.D., Ph.D., Great Ormond Street Hospital, London; Paolo Cravedi, M.D., Ph.D., and Carolina Purroy, M.D., Ph.D., Icahn School of Medicine at Mount Sinai; and Valeria Sordi, Ph.D., Lorenzo Piemonti, M.D., Ph.D., and Antonio Citro, Ph.D., IRCCS San Raffaele Scientific Institute, Milan, Italy.

Wake Forest Baptist Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to